Researchers at Washington University School of Medicine, in Saint Louis, in Estados Unidos, identified that obesity significantly accelerates the progression of Alzheimer disease. The study analyzed blood biomarkers in participants over five years and revealed faster increases in overweight individuals.
The research followed 407 volunteers and used blood tests to monitor proteins associated with neurodegeneration. The results indicate that obesity contributes to more intense biochemical changes, even before the appearance of clinical symptoms.
- pTau217: 29% to 95% faster increase in obese people.
- NfL: 24% increase in progression rate.
- GFAP: changes linked to brain inflammation.
These data reinforce the importance of accessible tests for early identification of the disease.
Mechanisms involved in acceleration
Obesity promotes chronic neuroinflammation that interferes with beta-amyloid protein metabolism in the brain. Essa inflammation alters the function of neurons and astrocytes, accelerating the accumulation of plaques characteristic of Alzheimer.
Additional studies indicate that excess body fat increases systemic inflammatory factors. Esses factors cross the blood-brain barrier and contribute to progressive neuronal damage.
Blood biomarkers analyzed
Blood tests focused on specific proteins that indicate pathological changes in the brain. pTau217 stands out as a sensitive marker for diagnosing and monitoring disease progression.
Neurofilament light chain (NfL) reflects direct neuronal damage. Já GFAP, expressed in astrocytes, signals inflammatory reactions associated with obesity.
These biomarkers showed greater sensitivity than positron emission tomography (PET) imaging. Eles detect biochemical changes in early stages of the pathology.
Longitudinal study results
Participants with obesity showed accelerated rates of increase in plasma biomarkers. pTau217 recorded elevations up to 95% faster compared to individuals without obesity.
Beta-amyloid accumulation also occurred more intensely in this group. Inicialmente, lower biomarker levels were observed due to greater blood volume, but progression accelerated over time.
The research followed volunteers for five years at Alzheimer’s Disease Neuroimaging Initiative. The data confirm obesity as a modifiable factor that directly influences the trajectory of the disease.
Comparison with traditional methods
Blood tests revealed greater accuracy in capturing early changes linked to obesity. Diferentemente of PET, which detects protein accumulation, plasma tests identify early biochemical variations.
This approach offers practical advantages in clinical studies. The tests are less invasive and more affordable than advanced imaging techniques.
Implications for early detection
Early identification allows preventive interventions in high-risk groups. Biomarker monitoring in obese individuals can guide weight reduction strategies.
Research indicates potential application in other neurodegenerative diseases. Similar inflammatory conditions occur in conditions such as Parkinson and multiple sclerosis.
Associated risk factors
Obesity in middle age emerges as a central element in the acceleration of Alzheimer. Estudos longitudinal studies reinforce this association with data from blood biomarkers.
Other factors include hypertension and diabetes, which are often linked to being overweight. The combination increases the risk of rapid progression of brain pathology.
- Body weight control.
- Regular physical activity.
- Balanced diet.
- Periodic medical monitoring.
These measures contribute to reducing systemic inflammation and preserving brain health.
Advances in diagnostic testing
Blood tests based on pTau217 have gained validation in specialized clinics. Pesquisas Brazilian and international studies confirm accuracy greater than 90% in early diagnoses.
The integration of these exams into clinical practice facilitates patient monitoring. Eles complement traditional cognitive assessments and brain imaging.
The accessibility of plasma tests represents a significant advance. Eles allow screening of larger populations without the need for complex equipment.
The research was presented at the Radiological Society of North America conference. The findings highlight obesity as a priority target in Alzheimer prevention strategies.
Recent advances in blood biomarkers pave the way for personalized treatments. Detection of changes accelerated by obesity guides specific interventions in asymptomatic phases of the disease, with the potential to slow neurodegenerative progress and improve the quality of life for millions of people at risk.
